Lymphoma covers more than 70 different cancers of the immune system, and treatment varies enormously by type — some grow slowly and need only watchful waiting, while aggressive forms can be cured with chemotherapy. CAR-T cell therapy, which reprograms a patient's own immune cells, is now standard for several relapsed lymphomas.
What's actually going on in research
Researchers are testing CAR-T therapy earlier in treatment, bispecific antibodies that pull immune cells onto cancer cells, and chemotherapy-free combinations for older patients. Studies are also looking at shorter treatment courses for curable lymphomas to reduce long-term side effects, and at new approaches for rare subtypes that have had fewer options.
CAR-T cell therapy
A patient's own immune cells are removed, reprogrammed to recognize lymphoma, and infused back. It is curing some patients whose disease came back after every other treatment.
Bispecific antibodies
These drugs grab a cancer cell with one arm and a T-cell with the other, forcing the immune system to attack. They work in some patients whose disease has resisted CAR-T.
Chemo-free regimens
Combinations of targeted drugs are matching or beating chemotherapy in some lymphomas, with fewer hospital visits and milder side effects. This is especially important for older or frailer patients.
What to know before you search
Eligibility depends heavily on the specific lymphoma subtype (such as DLBCL, follicular, mantle cell, Hodgkin), prior treatments, and overall health. A pathology report is usually required.
What types of trials are currently open
- Treatment trials — Testing new drugs, antibody therapies, or cell therapies in people with lymphoma to see if they work better than current treatment.
- CAR-T and cell therapy trials — Studies of immune cells engineered to attack lymphoma, often for people whose disease has come back.
- Maintenance trials — Testing whether continuing a treatment after remission lowers the chance the lymphoma returns.
- Supportive care trials — Testing ways to reduce infections, fatigue, and other complications during and after treatment.
- Observational studies — Following patients over time to learn how different lymphomas behave and respond to treatment.
Recently added Lymphoma trials
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.
Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
This is a single-arm, prospective, phase 2 clinical trial evaluating the improvement of survival outcomes of blinatumomab combined with chemotherapy as a full-course treatment regimen in patients with newly diagnosed Philadelphia chromosome-negative (Ph-negative) B-cell precursor acute lymphoblastic leukemia (B-ALL). The study adopts a "reduced-dose chemotherapy + full-course immunotherapy" strategy: induction therapy with reduced-dose chemotherapy combined with blinatumomab to improve remission rate and tolerability; consolidation therapy with alternating Hyper-CVAD (A/B) regimen，blinatumomab and sequential CD19-directed CAR-T therapy to deepen minimal residual disease (MRD) clearance; allogeneic hematopoietic stem cell transplantation (allo-HSCT) for some patients (e.g., KMT2A rearrangement, TP53 mutation, persistent MRD positivity, MRD recurrence); and no maintenance therapy. The primary endpoint is 2-year relapse-free survival (RFS). Secondary endpoints include 2-year overall survival (OS), the proportion and time to achieve complete response (CRc), and the proportion and time to achieve minimal residual disease (MRD) negativity. The trial plans to enroll 101 patients aged 15-65 years to demonstrate improved survival outcomes compared with historical controls .
Find Lymphoma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.